Navigation Links
Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer

BALTIMORE, April 3, 2008 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Bruce A. Peacock as its Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Peacock is a Venture Partner with SV Life Sciences Advisors, LLC. Previously, he served as the CEO or was a member of the senior management team for several successful entrepreneurial healthcare companies operating in therapeutic, diagnostic and service areas including The Little Clinic, Adolor Corporation, Orthovita, Inc., Cephalon, Inc., and Centocor, Inc.

"Mr. Peacock brings a wealth of experience and leadership with a proven track record of success," said Dan Janney of Alba's Board of Directors. "His experience in leading successful research and development and commercial infrastructures will be invaluable to Alba."

In a related announcement, Blake M. Paterson, MD, Alba's CEO and Co- Founder since its inception in 2004, has left the company to pursue other advisory and entrepreneurial interests. Since founding the Company, Dr. Paterson has raised over $40 million in funding for the Company and under his direction and leadership Alba has grown into a thriving Baltimore biotechnology company with 45 employees in its headquarters at the University of Maryland BioPark. This growth has led to the achievement of significant milestones including successful proof-of-concept for Alba's clinical candidate, larazotide acetate in celiac disease and the establishment of a licensing and collaboration agreement worth up to $325 million with Shire Pharmaceuticals.

"The addition of Mr. Peacock to the Alba management team will position the Company for the next level of financial and developmental success. I look forward to continuing to support the Alba team in their endeavors, as founder and past president," said Dr. Blake Paterson.

Dr. Lutz Giebel of Alba's Board of Directors commented, "We are extremely grateful to Blake for his commitment, dedication, vision and passion for the broad technology platform Alba has created and for helping to create medicines for patients with unmet medical needs. We will continue to count on his valuable perspective as the Company moves forward."

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Contact: Wendy Perrow, MBA

Phone: 410-878-9850


Web site:

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... Tampa, Florida (PRWEB) , ... November 24, 2015 ... ... its biggest event of the year and one of the premier annual events ... USA, and ran from 8–11 November 2015, where ISPE hosted the largest number ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader ... five states to develop and pitch their BIG ideas to improve health and wellness ... competing for votes to win the title of SAP's Teen Innovator, an all-expenses paid ...
(Date:11/24/2015)... TEL AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. ... be held on December 29, 2015 at 11:00 a.m. Israel ... & Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... , election of Eric Paneth and Izhak Tamir ... and Rami Skaliter as external directors; , approval of an ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):